Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Patritumab Deruxtecan ADC Compared to Chemotherapy or Trastuzumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of patritumab deruxtecan antibody-drug conjugate (ADC) compared to chemotherapy or trastuzumab deruxtecan (T-DXd; Enhertu®) ADC.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose cancer has progressed while receiving a CDK4/6 inhibitor and hormone therapy. You must not have a BRCA mutation and be eligible for treatment with a PARP inhibitor. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patritumab deruxtecan, by IV, every 3 weeks for 13 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Control</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of chemotherapy or trastuzumab deruxtecan (T-DXd; Enhertu®), for 13 months</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells. Patritumab deruxtecan is an ADC that binds to HER3, which is found on many breast cancer cells.</li> <li class="seamTextUnorderedListItem">For participants in the control group, the schedule for receiving the drug will vary depending on the drug.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07060807' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.merck.com/research/product-pipeline/' target='_blank'>Merck: Patritumab deruxtecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Antibody-Drug Conjugates</a> </li></ul>
1

Patritumab Deruxtecan ADC Compared to Chemotherapy or Trastuzumab Deruxtecan for Advanced HR+, HER2- Breast Cancer

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
Icon

Nearest Location from 94107:
346 miles
Los Angeles Hematology Oncology Medical Group ( Site 0026)
Los Angeles, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT07060807

Icon

Phase III

HELP GUIDE